Target intelligence / Profile preview

HECT domain E3 ubiquitin protein ligase 3 (HECTD3)

Target
HECTD3
Molecular classification
Enzyme, E3 ubiquitin ligase, HECT (Homologous to E6AP C-terminus) domain-containing protein
01

Overview

HECT domain E3 ubiquitin protein ligase 3 (HECTD3) is an enzyme in the HECT family of E3 ubiquitin ligases, characterized by possession of a C-terminal HECT domain that forms a thioester intermediate with ubiquitin to catalyze its transfer from an E2 conjugating enzyme to substrate proteins[4]. This activity controls protein fate—often marking proteins for degradation by the proteasome, but also modulating signaling, cell-cycle processes, and protein activity or localization[7][8]. The HECT ligase family plays pivotal roles in cellular homeostasis and pathophysiology, with individual members implicated in cancer and other diseases[1][3][8]. HECTD3 belongs to the “other” subfamily of the HECT E3 ligases, distinguished from the NEDD4 and HERC subfamilies by its unique N-terminal architecture[1][2][3]. While the full scope of HECTD3-specific biologic and clinical roles is still being investigated, dysregulation of HECT E3 ligases broadly is linked to oncogenesis, neurodegenerative disease, and other pathogenic processes[1][8].

Other names
HECT domain-containing protein 3HECT-type E3 ubiquitin transferase HECTD3FLJ21156
02

Mechanism of action

Catalyzes transfer of ubiquitin from an E2 conjugating enzyme to substrate proteins via a catalytic cysteine, forming a thioester intermediate. Targets substrate proteins for ubiquitin-mediated degradation or functional modification[7][8]

03

Biological functions

Protein ubiquitinationRegulation of protein degradationCell signaling modulationControl of protein turnover
04

Disease associations

CancerOther (possible involvement in additional disease processes, as HECT E3 ligases are broadly implicated in various pathologies)
05

Safety considerations

Broad role in essential cellular processes may result in toxicity if inhibited non-selectivelySpecific safety concerns are not yet well characterized for HECTD3

Beyond the preview

Go deeper on HECT domain E3 ubiquitin protein ligase 3 (HECTD3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HECT domain E3 ubiquitin protein ligase 3 (HECTD3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call